Edition:
United Kingdom

Health

Jeff Mason is a White House Correspondent for Reuters and the 2016-2017 president of the White House Correspondents’ Association. He was the lead Reuters correspondent for President Barack Obama's 2012 campaign and interviewed the president at the White House in 2015. Jeff has been based in Washington since 2008, when he covered the historic race between Obama, Hillary Clinton and John McCain. Jeff started his career in Frankfurt, Germany, where he covered the airline industry before moving to Brussels, Belgium, where he covered the European Union. He is a Colorado native, proud graduate of Northwestern University and former Fulbright scholar.

Twitter handle: @jeffmason1

01 Dec 2017

Cancer drug prompts 'drastic' HIV decrease in lung cancer patient

LONDON, Dec 1 Doctors in France have found the first evidence that a drug normally used to treat lung, kidney or skin cancer may be able to eradicate HIV-infected cells in people with the AIDS virus.

28 Nov 2017

Europe's HIV epidemic growing at alarming rate, WHO warns

LONDON, Nov 28 The number of people newly diagnosed with HIV in Europe reached its highest level in 2016 since records began, showing the region's epidemic growing "at an alarming pace", health officials said on Tuesday.

23 Nov 2017

Avatars can help schizophrenia patients control threatening voices

By Kate Kelland, Health and Science Correspondent LONDON, Nov 23 An experimental therapy for people with schizophrenia that brings them face to face with a computer avatar representing the tormenting voices in their heads has proved promising in early stage trials.

13 Nov 2017

Bill Gates makes $100 million personal investment to fight Alzheimer's

LONDON, Nov 13 Billionaire Microsoft co-founder Bill Gates is to invest $50 million in the Dementia Discovery Fund, a venture capital fund that brings together industry and government to seek treatments for the brain-wasting disease.

09 Nov 2017

Large U.S. farm study finds no cancer link to Monsanto weedkiller

LONDON, Nov 9 A large long-term study on the use of the big-selling weedkiller glyphosate by agricultural workers in the United States has found no firm link between exposure to the pesticide and cancer, scientists said on Thursday.

09 Nov 2017

U.S. farm study finds no firm cancer link to Monsanto weedkiller

LONDON, Nov 9 A large long-term study on the use of the big-selling weedkiller glyphosate by agricultural workers in the United States has found no firm link between exposure to the pesticide and cancer, scientists said on Thursday.

07 Nov 2017

WHO seeks new director for cancer agency facing U.S. scrutiny

LONDON The World Health Organization (WHO) is seeking a new leader for its France-based cancer research agency to replace the current director, Chris Wild, from January 2019.

07 Nov 2017

Stop using antibiotics in healthy animals, WHO urges farmers

LONDON, Nov 7 The World Health Organization urged farmers on Tuesday to stop using antibiotics to promote growth and prevent disease in healthy animals because the practice fuels dangerous drug-resistant superbug infections in people.

22 Sep 2017

A daily half hour's exercise could prevent 1 in 12 early deaths, study shows

LONDON, Sept 22 People who exercise five days a week for 30 minutes significantly reduce their risk of dying early and of developing heart disease, even if a sports club or gym is not an option, according to a new international study.

20 Sep 2017

Scientists edit embryos' genes to study early human development

LONDON, Sept 20 British scientists have used a genome editing tool known as CRISPR/Cas9 to knock out a gene in embryos just a few days old, testing the technique's ability to decipher key gene functions in early human development.

  • Europe
  • U.S.
  • Asia
  • Sectors
Stock Search
FTSE 100 7,500.41 + 46.93 +0.63%
DAX 13,183.53 + 59.88 +0.46%
CAC 40 5,427.19 + 40.36 +0.75%
TR Europe 183.90 -0.26 -0.14%
GBP/USD 1.3383 -0.04%
GBP/EUR 1.1375 -0.04%
EUR/USD 1.1764 +0.00%
Gold 1,245.90 -3.90 -0.31%
Oil 57.45 +0.31 +0.54%
Corn 335.75 +0.00 +0.00%